FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.

Publication

FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.

Journal Paper/Review - May 9, 2018

Schneider Paul M, Eshmuminov Dilmurodjon, Rordorf Tamara, Vetter Diana, Veit-Haibach Patrick, Weber Achim, Bauerfeind Peter, Samaras Panagiotis, Lehmann Kuno

Citation

Schneider P, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC cancer 2018; 18:548.

Type

Journal Paper/Review (English)

Journal

BMC cancer 2018; 18

Publication Date

May 9, 2018

Issn Electronic

1471-2407

Pages

548

Brief description/objective

Pathologic response to neoadjuvant chemotherapy (neoCTX) is a prognostic factor in many cancer types, and early prediction would help to modify treatment. In patients with gastric and esophagogastric junction (AEG) cancer, the accuracy of FDG PET-CT to predict early pathologic response after neoadjuvant chemotherapy (neoCTX) is currently not known.